- Published on
Emergency and Acute Medicine – Babesiosis
Overview And Key Concepts
Babesiosis is a tick-borne infection caused by intraerythrocytic protozoa (Babesia spp.) that invade and lyse red blood cells. Illness ranges from asymptomatic infection to severe, life-threatening disease, largely determined by the Babesia species involved and the patient’s immune status. About half of infected children and roughly one-quarter of infected adults may have no symptoms. Mild to moderate illness typically occurs in immunocompetent patients, is often self-limited or responds to antibiotics, and has mortality usually under 5%. Severe disease is commonly defined by prolonged hospitalization (more than 2 weeks), ICU stay (more than 2 days), or death, and is strongly associated with immune compromise such as splenectomy, malignancy, HIV, hemoglobinopathies, or chronic heart, lung, or liver disease. Additional higher-risk groups include neonates, adults older than 50, and patients receiving immunosuppressive medications (including rituximab or anticytokine agents such as etanercept or infliximab). In immunosuppressed patients, mortality may reach about 21%. Complications occur in about half of hospitalized patients, most commonly ARDS and DIC, and may also include CHF, coma, liver failure, renal failure, and splenic rupture. In endemic areas, consider co-infection with other tick-borne illnesses—Lyme disease may present with an associated rash, and human granulocytic anaplasmosis may cause more protracted symptoms with leukopenia.
Causes And Pathophysiology
Human babesiosis is most often due to Babesia microti in the Northern and Midwestern United States (the most common cause in the US), Babesia divergens in Europe, and Babesia duncani on the northern Pacific coast of the US, with reported cases from Asia, Africa, Australia, and South America. Animal reservoirs include white-footed mice and white-tailed deer for B. microti, and cattle and rats for B. divergens. Transmission most commonly occurs via Ixodes ticks; these ticks require a blood meal at each life stage (larva, nymph, adult). Most human cases follow nymph bites in late spring through summer, though adult ticks can also transmit infection. After inoculation, protozoa enter the bloodstream, invade erythrocytes, mature and divide, then exit RBCs—leading to membrane injury, hemolysis, hemoglobinuria, and hemolytic anemia. Damaged RBCs become less deformable and are typically cleared by the spleen; asplenic patients cannot clear infected cells effectively and therefore develop more severe disease. RBC damage may also contribute to microvascular stasis and secondary ischemic injury to organs such as the liver, spleen, heart, kidney, or brain. Transmission can also occur through transfusion of RBCs or platelets; more than 150 transfusion-associated cases have been reported since 1979, with most occurring since 2000. B. microti is the most common transfusion-transmitted pathogen, and donors may have low-level parasitemia that is not visible on smear yet remains infectious; recipients are often immunocompromised or have significant comorbidities, increasing severity. In pediatrics, transmission can occur in utero or during delivery, with cases reported in very young infants (as young as 4 weeks).
Clinical Presentation And Assessment
Symptoms usually begin gradually with malaise and fatigue, along with fever that may reach 105°F (40.6°C), typically 1–4 weeks after a tick bite or 1–9 weeks after transfusion of contaminated blood products. Common symptoms include chills and sweats, headache, anorexia, nonproductive cough, arthralgia, and nausea. Less common features include vomiting, sore throat, abdominal pain, conjunctival injection, photophobia, weight loss, emotional lability, depression, and hyperesthesia. History should specifically address travel to or residence in an endemic region within the prior 2 months (especially spring and summer) and any blood product transfusion within the prior 6 months. Consider babesiosis in shock or sepsis-like presentations when this history is present, particularly if severe-disease risk factors exist. On exam, fever is the most frequent finding; hepatosplenomegaly, pharyngeal erythema, jaundice, and ocular findings (retinopathy with splinter hemorrhages or retinal infarcts) may be present. Rash can occur, including petechiae or ecchymosis; erythema chronicum migrans suggests concurrent Lyme disease. Severe illness may present with tachypnea, hypoxia, hypotension, and altered mental status.
Essential Diagnostic Approach
Diagnosis is primarily established by microscopy of a thin blood smear stained with Giemsa or Wright stain to identify Babesia organisms. If smears are negative, PCR testing can be used. If both microscopy and PCR are negative but suspicion persists, indirect immunofluorescent antibody testing may help by detecting babesial antigens.
Interpretation Of Tests
On microscopy, intraerythrocytic parasites may appear round, oval, or pear-shaped. A budding tetrad (“Maltese cross”) is diagnostic for babesiosis but is not commonly seen. The most typical appearance is intraerythrocytic round or oval (pyriform) ring forms with pale blue cytoplasm and a red-staining nucleus; extracellular parasites may be seen with high parasitemia. Parasitemia is often 1–10% but can be as high as 80%, and may be under 1% early in disease. Ring forms can resemble Plasmodium falciparum malaria, but babesiosis lacks pigment (hemozoin) deposits. PCR amplification of the babesial 18S rRNA gene is more sensitive than microscopy, may return within 24 hours, and is particularly useful when parasitemia is low. Serology via indirect immunofluorescent antibody testing can assist when microscopy and PCR are negative; IgM is usually detectable about 2 weeks after illness onset, IgG titers ≥1:256 suggest recent or active infection, and IgM titers ≥1:64 suggest acute infection. Common nonspecific laboratory abnormalities include hemolytic anemia (low hematocrit/hemoglobin, low haptoglobin, elevated reticulocyte count, elevated LDH, elevated total bilirubin), thrombocytopenia, elevated liver tests (alkaline phosphatase, transaminases, LDH, bilirubin), urinalysis abnormalities (hemoglobinuria and proteinuria), elevated BUN/creatinine suggesting renal impairment, and hyperkalemia from massive hemolysis.
Conditions To Consider
Important alternatives include malaria and other tick-borne illnesses such as Lyme disease, human granulocytic anaplasmosis, ehrlichiosis, Rocky Mountain spotted fever, Colorado tick fever, Q fever, tularemia, relapsing fever, and typhoid fever, as well as other causes of acute hemolytic anemia.
Initial Management And Emergency Care
Prehospital priorities include ensuring airway patency in respiratory distress, providing supplemental oxygen and ventilatory support as needed, and treating shock with IV access and an initial 0.9% normal saline bolus (500 mL in adults; 20 mL/kg in children). In the ED, provide airway and ventilatory support for acute respiratory distress, establish IV access in patients with severe disease or high-risk features, give IV fluids and vasopressors for shock when needed, and place severe cases on cardiac monitoring because cardiac ischemia and arrhythmias can occur. Use antipyretics for fever. Initiate antibiotic therapy in symptomatic patients after confirmation by smear microscopy or PCR.
Definitive Therapy And Medications
For mild to moderate disease, oral atovaquone plus azithromycin for 7–10 days is preferred. Clindamycin plus quinine is an effective alternative but frequently causes adverse effects (tinnitus, vertigo, gastroenteritis) and may require dose reduction or discontinuation in up to one-third of patients. For severe disease, IV clindamycin plus oral quinine for 7–10 days is recommended; IV quinine can be used but may provoke ventricular arrhythmias and requires QT monitoring. RBC exchange transfusion is indicated for parasitemia greater than 10%, hemoglobin less than 10 g/dL, or pulmonary, renal, or hepatic complications. Persistent or relapsing disease can occur in immunocompromised patients; treat for at least 6 weeks and continue therapy for 2 weeks after the last positive smear, using standard regimens. Asymptomatic infection generally does not require antibiotics unless parasitemia persists on smear for more than 3 months. Medication options include acetaminophen 500 mg PO q4–6h (children 10–15 mg/kg per dose; do not exceed 5 doses per 24 hours; adult max 4 g/day), atovaquone 750 mg PO BID for 7 days (children 20 mg/kg per dose; max 750 mg/dose), azithromycin 500 mg PO day 1 then 250 mg PO daily for 6 days (children 10 mg/kg day 1 max 500 mg, then 5 mg/kg daily max 250 mg), clindamycin 300–600 mg IV q6h or 600 mg PO q8h for 7–10 days (children 7–10 mg/kg q6–8h), ibuprofen 400 mg PO q6–8h PRN (children 20–40 mg/kg/day), and quinine 650 mg PO q8h for 7–10 days (children 25 mg/kg/day).
Disposition And Follow-Up Planning
Admit patients with parasitemia above 4%, severe anemia (hemoglobin under 10 g/dL), significant symptoms or complications, or those requiring exchange transfusion, including cases with respiratory distress, hypotension or shock, new renal insufficiency or hepatic failure, altered mental status, or severe hemolysis (jaundice or hematuria). Consider admission even if these are absent when severe-risk features are present; elevated alkaline phosphatase, elevated WBC count, and male sex have been associated with more severe outcomes. Patients with asymptomatic, mild, or moderate disease may be discharged if parasitemia is under 4%, the spleen is intact, the patient is immunocompetent, and oral medications are tolerated. Immunodeficient patients are at increased risk for persistent or relapsing disease and should be referred to infectious disease. Arrange follow-up with primary care or infectious disease to monitor parasitemia after completing antibiotics in symptomatic patients and at 3 months in asymptomatic patients.
Clinical Cautions And Common Errors
Babesiosis can be rapidly fatal in asplenic patients, so maintain a high index of suspicion in this group. Consider babesiosis as a cause of respiratory distress or shock in patients with relevant travel or exposure in endemic regions. Early in infection, blood smears may be negative because parasitemia can be very low, so negative microscopy does not exclude disease when clinical suspicion remains high.
Overview And Key Concepts
Babesiosis is a tick-borne infection caused by intraerythrocytic protozoa (Babesia spp.) that invade and lyse red blood cells. Illness ranges from asymptomatic infection to severe, life-threatening disease, largely determined by the Babesia species involved and the patient’s immune status. About half of infected children and roughly one-quarter of infected adults may have no symptoms. Mild to moderate illness typically occurs in immunocompetent patients, is often self-limited or responds to antibiotics, and has mortality usually under 5%. Severe disease is commonly defined by prolonged hospitalization (more than 2 weeks), ICU stay (more than 2 days), or death, and is strongly associated with immune compromise such as splenectomy, malignancy, HIV, hemoglobinopathies, or chronic heart, lung, or liver disease. Additional higher-risk groups include neonates, adults older than 50, and patients receiving immunosuppressive medications (including rituximab or anticytokine agents such as etanercept or infliximab). In immunosuppressed patients, mortality may reach about 21%. Complications occur in about half of hospitalized patients, most commonly ARDS and DIC, and may also include CHF, coma, liver failure, renal failure, and splenic rupture. In endemic areas, consider co-infection with other tick-borne illnesses—Lyme disease may present with an associated rash, and human granulocytic anaplasmosis may cause more protracted symptoms with leukopenia.
Causes And Pathophysiology
Human babesiosis is most often due to Babesia microti in the Northern and Midwestern United States (the most common cause in the US), Babesia divergens in Europe, and Babesia duncani on the northern Pacific coast of the US, with reported cases from Asia, Africa, Australia, and South America. Animal reservoirs include white-footed mice and white-tailed deer for B. microti, and cattle and rats for B. divergens. Transmission most commonly occurs via Ixodes ticks; these ticks require a blood meal at each life stage (larva, nymph, adult). Most human cases follow nymph bites in late spring through summer, though adult ticks can also transmit infection. After inoculation, protozoa enter the bloodstream, invade erythrocytes, mature and divide, then exit RBCs—leading to membrane injury, hemolysis, hemoglobinuria, and hemolytic anemia. Damaged RBCs become less deformable and are typically cleared by the spleen; asplenic patients cannot clear infected cells effectively and therefore develop more severe disease. RBC damage may also contribute to microvascular stasis and secondary ischemic injury to organs such as the liver, spleen, heart, kidney, or brain. Transmission can also occur through transfusion of RBCs or platelets; more than 150 transfusion-associated cases have been reported since 1979, with most occurring since 2000. B. microti is the most common transfusion-transmitted pathogen, and donors may have low-level parasitemia that is not visible on smear yet remains infectious; recipients are often immunocompromised or have significant comorbidities, increasing severity. In pediatrics, transmission can occur in utero or during delivery, with cases reported in very young infants (as young as 4 weeks).
Clinical Presentation And Assessment
Symptoms usually begin gradually with malaise and fatigue, along with fever that may reach 105°F (40.6°C), typically 1–4 weeks after a tick bite or 1–9 weeks after transfusion of contaminated blood products. Common symptoms include chills and sweats, headache, anorexia, nonproductive cough, arthralgia, and nausea. Less common features include vomiting, sore throat, abdominal pain, conjunctival injection, photophobia, weight loss, emotional lability, depression, and hyperesthesia. History should specifically address travel to or residence in an endemic region within the prior 2 months (especially spring and summer) and any blood product transfusion within the prior 6 months. Consider babesiosis in shock or sepsis-like presentations when this history is present, particularly if severe-disease risk factors exist. On exam, fever is the most frequent finding; hepatosplenomegaly, pharyngeal erythema, jaundice, and ocular findings (retinopathy with splinter hemorrhages or retinal infarcts) may be present. Rash can occur, including petechiae or ecchymosis; erythema chronicum migrans suggests concurrent Lyme disease. Severe illness may present with tachypnea, hypoxia, hypotension, and altered mental status.
Essential Diagnostic Approach
Diagnosis is primarily established by microscopy of a thin blood smear stained with Giemsa or Wright stain to identify Babesia organisms. If smears are negative, PCR testing can be used. If both microscopy and PCR are negative but suspicion persists, indirect immunofluorescent antibody testing may help by detecting babesial antigens.
Interpretation Of Tests
On microscopy, intraerythrocytic parasites may appear round, oval, or pear-shaped. A budding tetrad (“Maltese cross”) is diagnostic for babesiosis but is not commonly seen. The most typical appearance is intraerythrocytic round or oval (pyriform) ring forms with pale blue cytoplasm and a red-staining nucleus; extracellular parasites may be seen with high parasitemia. Parasitemia is often 1–10% but can be as high as 80%, and may be under 1% early in disease. Ring forms can resemble Plasmodium falciparum malaria, but babesiosis lacks pigment (hemozoin) deposits. PCR amplification of the babesial 18S rRNA gene is more sensitive than microscopy, may return within 24 hours, and is particularly useful when parasitemia is low. Serology via indirect immunofluorescent antibody testing can assist when microscopy and PCR are negative; IgM is usually detectable about 2 weeks after illness onset, IgG titers ≥1:256 suggest recent or active infection, and IgM titers ≥1:64 suggest acute infection. Common nonspecific laboratory abnormalities include hemolytic anemia (low hematocrit/hemoglobin, low haptoglobin, elevated reticulocyte count, elevated LDH, elevated total bilirubin), thrombocytopenia, elevated liver tests (alkaline phosphatase, transaminases, LDH, bilirubin), urinalysis abnormalities (hemoglobinuria and proteinuria), elevated BUN/creatinine suggesting renal impairment, and hyperkalemia from massive hemolysis.
Conditions To Consider
Important alternatives include malaria and other tick-borne illnesses such as Lyme disease, human granulocytic anaplasmosis, ehrlichiosis, Rocky Mountain spotted fever, Colorado tick fever, Q fever, tularemia, relapsing fever, and typhoid fever, as well as other causes of acute hemolytic anemia.
Initial Management And Emergency Care
Prehospital priorities include ensuring airway patency in respiratory distress, providing supplemental oxygen and ventilatory support as needed, and treating shock with IV access and an initial 0.9% normal saline bolus (500 mL in adults; 20 mL/kg in children). In the ED, provide airway and ventilatory support for acute respiratory distress, establish IV access in patients with severe disease or high-risk features, give IV fluids and vasopressors for shock when needed, and place severe cases on cardiac monitoring because cardiac ischemia and arrhythmias can occur. Use antipyretics for fever. Initiate antibiotic therapy in symptomatic patients after confirmation by smear microscopy or PCR.
Definitive Therapy And Medications
For mild to moderate disease, oral atovaquone plus azithromycin for 7–10 days is preferred. Clindamycin plus quinine is an effective alternative but frequently causes adverse effects (tinnitus, vertigo, gastroenteritis) and may require dose reduction or discontinuation in up to one-third of patients. For severe disease, IV clindamycin plus oral quinine for 7–10 days is recommended; IV quinine can be used but may provoke ventricular arrhythmias and requires QT monitoring. RBC exchange transfusion is indicated for parasitemia greater than 10%, hemoglobin less than 10 g/dL, or pulmonary, renal, or hepatic complications. Persistent or relapsing disease can occur in immunocompromised patients; treat for at least 6 weeks and continue therapy for 2 weeks after the last positive smear, using standard regimens. Asymptomatic infection generally does not require antibiotics unless parasitemia persists on smear for more than 3 months. Medication options include acetaminophen 500 mg PO q4–6h (children 10–15 mg/kg per dose; do not exceed 5 doses per 24 hours; adult max 4 g/day), atovaquone 750 mg PO BID for 7 days (children 20 mg/kg per dose; max 750 mg/dose), azithromycin 500 mg PO day 1 then 250 mg PO daily for 6 days (children 10 mg/kg day 1 max 500 mg, then 5 mg/kg daily max 250 mg), clindamycin 300–600 mg IV q6h or 600 mg PO q8h for 7–10 days (children 7–10 mg/kg q6–8h), ibuprofen 400 mg PO q6–8h PRN (children 20–40 mg/kg/day), and quinine 650 mg PO q8h for 7–10 days (children 25 mg/kg/day).
Disposition And Follow-Up Planning
Admit patients with parasitemia above 4%, severe anemia (hemoglobin under 10 g/dL), significant symptoms or complications, or those requiring exchange transfusion, including cases with respiratory distress, hypotension or shock, new renal insufficiency or hepatic failure, altered mental status, or severe hemolysis (jaundice or hematuria). Consider admission even if these are absent when severe-risk features are present; elevated alkaline phosphatase, elevated WBC count, and male sex have been associated with more severe outcomes. Patients with asymptomatic, mild, or moderate disease may be discharged if parasitemia is under 4%, the spleen is intact, the patient is immunocompetent, and oral medications are tolerated. Immunodeficient patients are at increased risk for persistent or relapsing disease and should be referred to infectious disease. Arrange follow-up with primary care or infectious disease to monitor parasitemia after completing antibiotics in symptomatic patients and at 3 months in asymptomatic patients.
Clinical Cautions And Common Errors
Babesiosis can be rapidly fatal in asplenic patients, so maintain a high index of suspicion in this group. Consider babesiosis as a cause of respiratory distress or shock in patients with relevant travel or exposure in endemic regions. Early in infection, blood smears may be negative because parasitemia can be very low, so negative microscopy does not exclude disease when clinical suspicion remains high.
0 Comments
